Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | P2443 | — |
late second dose of Twinrix was administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 63-year-old male patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Previously administered products included Twinrix (Patient received first dose on 12-JUL-2024). On 25-APR-2025, the patient received the 2nd dose of Twinrix. On 25-APR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose of Twinrix was administered). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-APR-2025 Pharmacist reported that a late second dose of Twinrix was administered to a patient. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccinations schedule.